BERLIN, February 17, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the ...

Our vision for our lead asset NOX-A12 remains clear: to secure approval for its use in glioblastoma patients through a strategic partnership with a pharmaceutical company, supported by ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) on February 14 and set a price target of $70.00. The company’s shares closed last ...

The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million ...

The mouse on the right with four times the normal muscle mass is placed with a normal mouse. Handout via REUTERS About a dozen drugmakers are developing new weight-loss treatments aimed at ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

1 Day ELTP 0.00% DJIA -0.26% Russell 2K 0.25% Health Care/Life Sciences 0.00% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended. J&J resumes ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), ...